Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schanza, LM; Seles, M; Stotz, M; Fosselteder, J; Hutterer, GC; Pichler, M; Stiegelbauer, V.
MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Int J Mol Sci. 2017; 18(11):
Doi: 10.3390/ijms18112495
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Stiegelbauer Verena
- Co-Autor*innen der Med Uni Graz
- Foßelteder Johannes
- Hutterer Georg
- Pichler Martin
- Seles Maximilian
- Stotz Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Renal cell carcinoma (RCC) are the most common renal neoplasia and can be divided into three main histologic subtypes, among which clear cell RCC is by far the most common form of kidney cancer. Despite substantial advances over the last decade in the understanding of RCC biology, surgical treatments, and targeted and immuno-therapies in the metastatic setting, the prognosis for advanced RCC patients remains poor. One of the major problems with RCC treatment strategies is inherent or acquired resistance towards therapeutic agents over time. The discovery of microRNAs (miRNAs), a class of small, non-coding, single-stranded RNAs that play a crucial role in post-transcriptional regulation, has added new dimensions to the development of novel diagnostic and treatment tools. Because of an association between Von Hippel-Lindau (VHL) genes with chromosomal loss in 3p25-26 and clear cell RCC, miRNAs have attracted considerable scientific interest over the last years. The loss of VHL function leads to constitutional activation of the hypoxia inducible factor (HIF) pathway and to consequent expression of numerous angiogenic and carcinogenic factors. Since miRNAs represent key players of carcinogenesis, tumor cell invasion, angiogenesis, as well as in development of metastases in RCC, they might serve as potential therapeutic targets. Several miRNAs are already known to be dysregulated in RCC and have been linked to biological processes involved in tumor angiogenesis and response to anti-cancer therapies. This review summarizes the role of different miRNAs in RCC angiogenesis and their association with the VHL gene, highlighting their potential role as novel drug targets.
- Find related publications in this database (using NLM MeSH Indexing)
- Angiogenesis Inhibitors - pharmacology
- Angiogenesis Inhibitors - therapeutic use
- Animals -
- Antineoplastic Agents - pharmacology
- Antineoplastic Agents - therapeutic use
- Carcinoma, Renal Cell - drug therapy
- Carcinoma, Renal Cell - genetics
- Carcinoma, Renal Cell - metabolism
- Carcinoma, Renal Cell - pathology
- Gene Expression Regulation, Neoplastic - drug effects
- Humans -
- Hypoxia-Inducible Factor 1 - metabolism
- Kidney Neoplasms - drug therapy
- Kidney Neoplasms - genetics
- Kidney Neoplasms - metabolism
- Kidney Neoplasms - pathology
- MicroRNAs - genetics
- Molecular Targeted Therapy -
- Neovascularization, Pathologic - drug therapy
- Neovascularization, Pathologic - genetics
- Neovascularization, Pathologic - metabolism
- Signal Transduction -
- Von Hippel-Lindau Tumor Suppressor Protein - metabolism
- Find related publications in this database (Keywords)
- renal cell carcinoma
- Von Hippel-Lindau
- angiogenesis
- microRNAs